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Sentinel lymph node involvement and a high Breslow index are
independent factors of risk for early relapse of melanoma
Abstract
AIM: The clinical relevance of sentinel lymph node (SLN) analysis was evaluated prospectively and
compared with other known risk factors of relapse in early stage melanoma. METHODS: Surgery was
guided by lymphoscintigraphy, blue dye and gamma probe detection. SLN were analysed by
haematoxylin eosin (HE) histochemistry and multimarker immunohistochemistry (IHC). Disease free
survival (DFS) was evaluated with Kaplan-Meier plots according to different parameters and Cox
analyses of variance. RESULTS: From 210 patients a total of 381 SLN were excised.
Lymphoscintigraphy identified all excised SLN with only 2 false positive lymphatic lakes. Fifty patients
(24%) had tumour positive SLN. With a mean follow-up of 31.3 months, 29 tumour recurrences were
observed, 19 (38%) in 50 SLN positive and 10 (6%) in 160 SLN negative patients. Strong predictive
factors for early relapse (p < 0.0005) were SLN positivity and a high Breslow index. CONCLUSION:
SLN tumour positivity is an independent factor of high risk for early relapse with a higher power of
discrimination than the Breslow index.
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Summary
Aim: The clinical relevance of sentinel lymph node (SLN)
analysis was evaluated prospectively and compared with
other known risk factors of relapse in early stage mel-
anoma. Methods: Surgery was guided by lymphoscinti-
graphy, blue dye and gamma probe detection. SLN were
analysed by haematoxylin eosin (HE) histochemistry and
multimarker immunohistochemistry (IHC). Disease free
survival (DFS) was evaluated with Kaplan-Meier plots ac-
cording to different parameters and Cox analyses of vari-
ance. Results: From 210 patients a total of 381 SLN were
excised. Lymphoscintigraphy identified all excised SLN with
only 2 false positive lymphatic lakes. Fifty patients (24%)
had tumour positive SLN. With a mean follow-up of 31.3
months, 29 tumour recurrences were observed, 19 (38%)
in 50 SLN positive and 10 (6%) in 160 SLN negative pa-
tients. Strong predictive factors for early relapse
(p <0.0005) were SLN positivity and a high Breslow
index. Conclusion: SLN tumour positivity is an indepen-
dent factor of high risk for early relapse with a higher power
of discrimination than the Breslow index.
Nuklearmedizin 2007; 46: 244–251
doi: 10.3413/nukmed-0095
Schlüsselwörter
Wächterlymphknoten, Melanom, Breslow-Index, Risiko-
faktor, Rezidiv
Zusammenfassung
Ziel: Die klinische Bedeutung des Wächterlymphkno-
ten(SLN)-Befalls wurde prospektiv in Bezug auf das Früh-
auftreten eines Rezidivs analysiert und mit anderen be-
kannten Risikofaktoren beim Melanom im Frühstadium
verglichen. Methode: Nach der Resektion, gestützt auf
Szintigraphie, Patentblau V und intraoperative Gamma-
Sondenmessung, wurden die SLN mit Hämatoxylin-
Eosin(HE)-Färbung und Multimarker-Immunohistochemie
(ICH) untersucht. Tumorfreie Überlebenszeit wurde für ver-
schiedene Parameter nach der Kaplan-Meier-Methode und
der Cox-Varianzanalyse analysiert. Ergebnisse: Bei 210
Patienten wurden 381 SLN untersucht. Die Szintigraphie
identifizierte alle Lymphknoten, mit zwei falsch positiven
Ergebnissen. Fünfzig Patienten (24%) wiesen einen Tu-
morbefall des SLN auf. Bei einer mittleren Beobachtungs-
zeit von 31,3 Monaten wurden 29 Rezidive festgestellt, da-
von 19 (38%) bei 50 SLN-positiven und 10 (6%) bei 160
SLN-negativen Patienten. Den höchsten prädiktiven Wert
(p <0,0005) für ein frühzeitiges Rezidiv wiesen SLN-Be-
fall und Breslow-Index auf. Schlussfolgerung: SLN-Befall
ist ein unabhängiger Risikofaktor für ein früh rezidivieren-
des Melanom mit besserer Diskriminanz als der Breslow-
Index.
SLN-Befall und hoher Breslow-
Index sind unabhängige
Risikofaktoren eines
Frührezidivs beim Melanom
T
he application of the sentinel
lymph node (SLN) technique to
melanoma has been introduced in
1992 by Morton et al. (7) and extended
with scintigraphy by Alex et al. in 1993
(1). The combination of lymphoscinti-
graphy with the blue dye technique allows
identifying the SLN in 95 to 100% of the
patients. Metastatic SLN have been found
in 16 to 21% of patients (5, 7, 9, 10,
12-14). In case of SLN positivity in mel-
anoma, SLN was the unique site of meta-
stasis in 50 to 87% of patients submitted
to elective lymphadenectomy. Fur-
thermore, metastases that bypassed the
SLN were found in less than 2% of pa-
tients (5, 9, 10, 13). These data show the
importance of SLN analysis in patients
with melanoma. The selective excision of
sentinel lymph node(s) offers several ad-
vantages compared to elective lymph
node dissection: First, the large majority
of patients without lymph node disease
will not undergo unnecessary lymph node
dissection, a procedure connected with a
high incidence of complications such as
wound infection, seroma formation and
lymphoedema. Secondly, the sentinel
node can be analysed most carefully
using multiple slicing combined with de-
tailed histologic and immunhistologic
analysis and reverse transcription-
polymerase chain reaction (RT-PCR).
Such an extended analysis cannot be ap-
plied routinely to the multiple nodes from
elective lymph node dissections.
Rousseau et al. (12) showed that strat-
ification of melanoma patients according
to the American Joint Committee on
Cancer (AJCC) staging criteria revealed an
increasing risk of SLN metastases with
successive stage groups. According to
these authors, the ability of the AJCC stag-
ing system to predict survival was likely
due to its ability to predict the risk of occult
nodal, notably SLN disease, given the sig-
nificant association of SLN status and sur-
vival. This interpretation again highlights
the clinical relevance of the SLN status in
melanoma.
With regard to disease free survival
(DFS) and overall survival (OS), no signifi-
cant difference was observed between pa-
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tients having undergone immediate com-
plete resection of lymph nodes of the pri-
mary basin and patients who first had sur-
gical resection and analysis of the SLN fol-
lowed by secondary elective lymph node
dissection in case of positivity (4).
Only a few studies focus on long-term re-
sults of selective sentinel node surgery due
to the recent development of the method and
the fact that randomised studies are on-
going. The goal of this prospective study
was to evaluate the relevance of SLN tu-
mour positivity in relapse risk assessment of
melanoma.
Patients, materials, methods
The study was performed in the frame of a
SLN protocol conducted by the Groupe Mél-
anome Lémanique. The study protocol was
approved by the ethical commission and pa-
tients gave their written, informed consent to
participate. Two hundred and ten successive
patients entered the study. Patients’character-
istics are shown in Table 1. None of the pa-
tients presented clinical or radiological evi-
dence of metastatic lymph node disease at the
moment of SLN excision. Breslow thickness
was comprised between 0.45 and 10.0 mm,
four patients could not be classified by this
parameter. Histology typing was: superficial
spreading in 89 patients among which 15 ul-
cerative, nodular in 69 patients including 23
ulcerative, acral-lentiginous in 23 patients in-
cluding six ulcerative. Six patients presented
other different histologies and 23 lesions
were not classified. Clark indices ranged
from II toV, six patients being not classified.
SLN triple detection technique
The SLN triple technique, including pre-
operative lymphoscintigraphy, blue color-
ation and per-operative detection with a
handheld gamma probe, was applied to all
patients. All lymphatic nodes identified by
the triple technique were considered SLN
and excised.
Lymphoscintigraphy was realised the
day before surgery using intradermic injec-
tion of
99m
Tc-microcolloid (Lymphoscint
Solco

, n = 54) or
99m
Tc-nanocolloid (Na-
nocoll

, n = 150) and Nanocis

, n = 6). An
activity of 10 MBq per site was injected at
two to six points, depending on lesion size.
Static imaging of 5 minutes using a matrix
of 256 × 256 and further static imaging of 2
minutes (matrix 256 × 256) combined with
an external transmission source was real-
ised. The location of the SLN(s) was/were
marked in ink on the skin.
The SLN(s) was/were localised peroper-
atively by radioactivity detection at the la-
belled site(s) using a portable probe „Neo-
probe 1000” (Neoprobe Corp., Dublin,
Ohio, USA) equipped with a detector of 11
mm diameter or the „pol.hi.tech. Scinti-
Probe MR-100” equipped with two detec-
tors of 11 and 18 mm diameter.
One or several slow (2 to 3 minutes) in-
tradermic injections of patent blue (Pat-
ent V
®
) or Evans blue (Evans
®
) were per-
formed around the melanoma site or the sur-
gical scar 10 to 15 minutes before surgery.
The SLN surgery was performed at the site
defined the day before using lymphoscinti-
graphy and the precise localisation deter-
mined with the hand held gamma probe and
visual detection of the dye.
Histopathology, further treatment
and follow up
All excised SLN were immediately sent for
histopathological examination without fix-
ation. Alternate slices of 2 mm thickness
throughout the SLN were subjected to his-
tology and immunohistology analysis.
Slices were paraffin embedded and 3 to 5
sections per slice subjected to classical his-
tology using haematoxyline-eosin (HE)
staining. Immunohistochemistry (IHC)
analysis was performed for protein S-100,
MART-1/Melan-A, Tyrosinase and HMB
45, except for nine patients for whom histol-
ogy alone was performed. MART-
1/Melan-A, Tyrosinase and HMB 45 are
proteins specifically expressed by mel-
anocytes and most melanoma while protein
S-100 is expressed by different neuroendo-
crine tissues and tumours.
Disease free survival was defined as in-
terval from surgery to first observation of
relapse. All patients presenting tumour-
negative SLN by HE and IHC criteria were
followed every 3 to 12 months by clinical
examination and whole body CT without
further treatment. Elective node dissection
was proposed to patients presenting tumour-
positive SLN by HE and/or IHC criteria, in-
dependently from the Breslow index.
Statistics
Different clinical and pathological factors
including age, sex, location and histologi-
cal classification of melanoma, Breslow
index, ulceration, number and tumour
positivity/negativity of SLN have been
analysed as predictive elements of disease
evolution. Analysis of DFS was performed
using the Kaplan-Meier method. Univari-
ate and multivariate analysis on the basis
of Cox’s proportional hazards regression
Tab. 1 Patient’s characteristics
total
sex men
women
age mean
range
melanoma
localization
upper extremity
lower extremity
number of
patients
210
107
103
053.7
015–79
039
074
Breslow
thickness (mm)
melanoma
histology
ulceration
trunc
head and neck
≤1.49
1.5–2.38
≥2.39
unknown
range
superficial spreading
nodular
acra-lentiginous
others
unclassable
unknown
yes
no
081
016
072
066
068
004
000.45–10
089
069
023
006
016
007
053
157
245
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model were used to associate covariates to
DFS. Breslow thickness was treated as a
continuous variable for both univariate and
multivariate analysis. P-values <0.05 were
considered significant. All analyses were
performed using the BMDP statistical
Software.
Results
In 210 patients, 385 SLN have been ident-
ified by lymphoscintigraphy. Two addi-
tional sites (0.5%) identified by lymphos-
cintigrapy as SLN were false positive and
corresponded to lymphatic lakes. Blue co-
loration detected 375/385 SLN (97%) and
gamma probe 377/385 (98%). Combined
blue coloration and/or the hand held probe
allowed the peroperative localization of
381 SLN (99%, 1.81 SLN per patient) that
were excised and analysed. For the other
four sites identified by lymphoscinti-
graphy (1%), complementary nodal sur-
gery did not allow to find a radioactive
lymph node.
Draining sites, post-surgical
complications
Single SLNs were detected in 102 patients,
two SLNs in 72 patients and more thand
three SLNs in 36 patients.A large number of
multiples draining sites were observed in
trunk and head & neck melanomas (Tab. 2).
Draining to three sites, all homolateral was
observed in three patients. 97% of the upper
and lower extremities drained to the axillary
and inguinal nodes, respectively, while
trunc melanomas drained preferentially to
axillary nodes (83%) and head and neck
melanomas to cervical nodes (44%).
Concerning morbidity after SLN resec-
tion, six cases of lymphocele (3%), four
cases of local infection (2%), one case of
allergy (grade I) against blue dye (0.5%),
one case of pulmonary embolism (0.5%)
and one case of scar pain (0.5%) were ob-
served.
Histopatholgy, resection of sites
A total of 68 (18%) tumour positive SLN
were observed by HE staining and/or IHC.
Fourty-three SLN were positive by HE
staining as well as IHC, 16 were positive by
IHC alone and nine were positive by HE
staining while immunohistology had not
been performed. Furthermore, 161 control
lymph nodes were excised and analysed
from 61 patients (2.6 control nodes per pa-
tient). All control nodes were negative by
HE and IHC. On a per patient basis, 50 pa-
tients out of 210 (24%) had positive nodes
by HE and/or IHC.
40/50 patients presenting metastases of
the SLN by HE/IHC criteria had comple-
mentary elective resection of all nodes in the
sites identified for SLN by lymphoscinti-
graphy. All complementary resections were
performed within three months of SLN sur-
gery. From three up to 47 nodes were ex-
cised at secondary node surgery. One or
more further positive nodes were found in
10 of these 40 patients (25%).
Relapse, SLN status, survival
Mean follow-up after SLN resection was
31.3 months (range: 6–66 months). Four pa-
tients were lost to follow up 4, 9, 29 and 32
months respectively after SLN surgery
without evidence of relapse and were enter-
ed considered in live as such in the survival
analysis. Out of 210 patients 29 relapsed
with local and/or distant disease one to 55
months after SLN surgery (Tab. 3).
We observed 19 relapses which occurred
in 50 SLN positive patients and 10 in 160
SLN negative patients. Fourty patients out
of 50 SLN positive patients accepted elec-
tive node resection. Ten of them were posi-
tive in the histopathological examination of
the complementary nodes. We observed
eight recurrences in the group of 10 positive
elective node resections (80%) and only
3/30 (10%) in the group of negative elective
node resections.
At evaluation, 196 of 210 patients were
alive. Thirteen patients had died from dis-
ease, 10 of 19 patients with relapse and posi-
tive SLN, three among the 10 patients who
relapsed despite negative SLN. One patient,
who was SLN negative and without evidence
of relapse, had died from an unrelated cause.
According to Kaplan-Meier analysis
the overall survival probability in our pa-
tient population was 92% at three years
(Fig. 1a). SLN status proved to be the most
significant predictive factor of relapse:
Relapse probability was 12% in SLN
negative and 54% in SLN positive patients
(p <0.0001). Already at one year relapse
probability in SLN positive patients was
high (25%), compared with only 3% in
SLN negative patients (Fig. 1b). The mean
Breslow index of all patients was 2.32 +
SD 1.53 mm. It was 2.06 + SD 1.40 mm for
patients with negative SLN, 3.15 + SD 1.69
mm in SLN positive (HE and/or IHC) pa-
tients and 3.4 + SD 1.86 mm in patients
whose tumour recurred.
DFS probability according to Breslow
index as a contiuous variable was highly
significant (p <0.0001). When evaluated
for three similar sized subgroups that pres-
ented Breslow indices of ≤1.49 (n = 72),
1.5 to 2.38 (n = 66) and ≥2.39 (n = 68) the
overall probability of relapse was 5, 25 and
37%, respectively. Relapse probability at
one year after surgery in these subgroups
was 0, 5 and 18%, respectively (Fig. 1c).
DFS according to sex was close to signifi-
cant (p = 0.06), relapse probability being
18 and 28% for women and men, respect-
ively (Fig. 1d).
Histology showed a small trend towards
significance (p = 0.21), relapse probability
Tab. 2
Lymphatic draining sites
localisation 1 site
upper extremity 036
lower extremity 071
trunc 049
head & neck 011
total 167
2 sites homolateral
03 (8%)
02 (3%)
09 (11%)
04 (27%)
18
2 sites bilateral
00
00
21 (25%)
01 (7%)
22
3 sites total
0
1 (1%)
2 (2%)
0
3
039
074
081
016
210
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being highest for nodular histology. Sur-
vival prediction showed no clear difference
in trend among the other histological sub-
groups. Primary melanoma localization
showed a similar trend of difference (p =
0.21) with the highest probability for re-
lapse for melanoma of the head and neck,
followed by lower and upper extremities
melanoma. The other parameters evaluated,
notably ulceration, age and number of SLN,
were far from reaching statistical signifi-
cance concerning probability of relapse.
In the multivariated analysis, the Cox
analysis indicated that the most important
risk factor was SLN positivity (p = 0.0001)
followed by the Breslow index (p = 0.0004)
and patient’s sex (p = 0.055).
When analysing the relapse probability
for the combination of Breslow index and
SLN positivity again in three similar sized
subgroups defined as
● SLN negative and Breslow index <1.5,
● SLN negative and Breslow index be-
tween 1.5 to 3.5,
● SLN positive and/or Breslow >3.5, re-
lapse probabilities were 3, 16 and 48%,
respectively (Fig. 1e).
Finally, SLN positivity in combination with
a Breslow index of ≥2.39 was observed in 28
patients, and 15 of these patients relapsed.
The Kaplan-Meyer analysis gave a very
high relapse probability of 72% for these
patients, the probability in the first year
being 42% with a 95% confidence interval
of between 25 and 63%.
Tab. 3 Major disease and survival parameters of 29 relapsed patients
patient
sex
01 F
02 F
03 M
04 F
05 M
melanoma
locali.
LE
LE
trunc
trunc
trunc
Breslow
1.47
2,27
5.1
3.8
3.2
ulcer histology number HE/IHC local distant
SLN relapse (month*) last control
in life (month*)
died from disease
(month*)
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
F
M
F
F
M
M
F
M
M
M
M
M
M
M
M
M
M
F
M
M
M
M
F
M
LE
UE
LE
H&N
LE
trunc
LE
LE
LE
UE
LE
LE
trunc
trunc
trunc
UE
H&N
LE
H&N
H&N
LE
trunc
LE
UE
2.5
2.32
4
2.7
2.5
4
6.5
2.4
2.9
5.5
9
4.4
3
2.2
4
2.3
1.8
2.3
1.2
2.2
2.3
1.95
8
2.8
no
no
no
no
yes
no
yes
yes
no
yes
no
yes
no
no
no
no
no
no
yes
no
no
no
yes
no
no
no
no
no
no
superficial s.
acra-lent
nodular
superficial s.
nodular
unknow
superficial s.
nodular
other
acra-lent
nodular
nodular
nodular
nodular
nodular
acra-lent
nodular
superficial s.
superficial s.
nodular
nodular
superficial s.
superficial s.
unclassable
superficial s.
nodular
superficial s.
nodular
nodular
1
1
2
1
2
1
1
1
4
2
1
2
1
3
2
1
1
2
3
2
1
1
1
3
2
2
3
1
1
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
N
N
N
N
N
N
N
N
N
N
P
ND
ND
ND
ND
P
P
P
P
P
P
P
ND
ND
ND
ND
N
N
N
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
13
49
06
06
13
05
12
27
05
02
04
08
16
08
10
34
18
26
23
08
36
26
20
34
04
01
06
07
17
13
11
01
27
33
02
25
15
16
19
42
26
34
55
27
59
51
34
22
18
46
33
43
20
47
42
39
34
34
31
55
34
63
18
24
08
15
03
41
19
21
21
12
32
elective
resect.
P: positive; N: negative; ND: not done; UE: upper extremity. LE: lower extremity; H&N: head and neck; *months after excision of SLN
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Discussion
This study aimed at evaluating SLN scinti-
graphy in early stage melanoma. A second
aim was the evaluation of the prevalence of
tumour recurrence in SLN positive patients.
Performed as multicenter study, scinti-
graphy was analysed as part of the triple
SLN detection method. Immunohisto-
chemical analysis was performed for four
parameters.
RT-PCR evaluation was performed in a
subgroup of these patients. These results
have been presented previously (11). Over-
all, we did not observe any particular differ-
ence of relapse probability between RT-
PCR positive and negative patients. None of
the RT-PCR positive patients with negative
HE/IHC evaluation presented a relapse in
this evaluation. In fact, the debate on the rel-
evance of PCR as a predictive factor for re-
lapse in melanoma patients remains open (2,
3). RT-PCR positive and HE/IHC negative
patients might represent a subgroup of pa-
tients with very minor disease. The survival
probability of these patients appears to be
better in the first years than that of HE/IHC
SLN positive patients, but they might be
prone to relapse at a later stage.
The lymphatic imaging of SLN in mel-
anoma patients allowed visualising all 381
SLN in this cohort of 210 patients in the
sense that no further SLN were detected by
the blue coloration method and the gamma
probe. However, while these latter methods
revealed essential and complementary in-
formation for surgery, a few SLN were
missed (1%) even when using the com-
bination of both of them. In the absence of
the peroperative SLN identification, selec-
tive surgery of the relevant lymph node
basin had to be performed and the histologi-
cal analysis of the multiple lymph nodes was
therefore suboptimal.
In view of the high detection rate of
>97% with each of the preoperative meth-
ods, one or the other method might be
chosen by the surgeon without major change
in the selective SLN resection rate. However,
the combination of blue coloration and
gamma probe technique allowed to resect
and analyse the highest percentage of SLN.
Scintigraphy had a false positive detection
Fig. 1 Overall survival (a) and disease free survival (b-e); vertical bars: 95% confidence interval
a) overall survival probability: 92% at three years
b) histology between negative and positive SLN patients; overall relapse probability (3 years): 10% and 45%
b)
a)
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rate of 2/385 (0.5%), both false positives
being due to lymphatic lakes. This already
low rate could possibly be further reduced by
using late imaging, however the gain might
be judged insufficient in this pathology.
In view of the favourable detection rate
of SLN by scintigraphy, it is confirmed here
that this method is essential in SLN surgery
of melanoma. It notably allowed in many pa-
tients to become aware of multiple draining
sites of melanoma, especially when situated
on the trunk and close to the median line.
However, also infrequent localisation of
SLN such as popliteal or humeral sites
could be identified and allowed the surgeon
to program the intervention adequately.
When considering the histopathological
examination, we found a clear difference
between the classical HE coloration and im-
munohistochemistry in favour of the latter
one. While all HE positive SLN that were
also examined by immunohistochemistry
were confirmed, the latter method detected
a significantly higher number of metastases.
We used the overall detection rate of these
two methods to correlate it with the clinical
outcome. The combination of both tech-
niques was necessary, since immunohisto-
chemistry could not be performed in a few
occasions.
In this series, 24% of patients presented
tumour positive SLN by HE/IHC criteria.
When analysing SLN positivity according
to histological criteria, nodular melanoma
showed the highest incidence of SLN posi-
tivity (35%), followed by acral-lentiginal
histology (26%) and superficial spreading
melanoma (16%). These results differ par-
tially from those described by Vuylsteke et
al. (14) who found similarly that nodular
melanoma had the highest probability for
SLN positivity, followed, however, by super-
ficial spreading in his series. Acral lentigi-
nal melanoma, which presented only 1% in
the patient population of Vuylsteke com-
pared with 11% in our group, had no par-
ticular tendency for SLN positivity.
In this study, primary melanoma located
on the legs as compared to other locali-
sations showed a higher incidence of SLN
positivity. A correlation of SLN positivity
with primary tumours on the appendices has
been described previously by Rousseau et
al. (12).
Fig. 1 c) relapse probability (3 years) of 4, 18, and 37% in the subgroups with Breslow indices of ≤1.49 (n = 72),
1.5 to 2.38 (n = 66) and ≥2.39 (n = 68)
d) relapse probability according to sex (3 years): 12 and 28% for women and men
c)
d)
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We observed 29 tumour relapses one to 55
months post surgery of primary melanoma.
The univariate and multivariate analysis
showed that the highest risk factors for re-
lapse were those of SLN positivity and a high
Breslow index. SLN positivity and a Breslow
index above 2.38 turned out as strong predic-
tive factors of early relapse in agreement with
the observations of Vuylsteke et al. (14),
Mozzillo et al. (8), Rousseau et al. (12) and
Morton et al. (6). Ulceration has been de-
scribed as another predictive factor of relapse
by two of the three mentioned authors (8, 14).
However, this was not the case in the patient
population presented here. This study in-
cluded 53 patients with ulcerated melanoma.
Their risk of relapse appeared only margin-
ally higher (p = 0.58) than that of patients
without ulceration.
Relapse probability according to pa-
tient's sex was close to significant (p = 0.06)
with more than 50% increased relapse prob-
ability for men compared with women. Con-
cerning tumour histology, some tendency
was observed (p = 0.21), nodular melanoma
showing a highest probability of tumour re-
currence. However, the number of patients
per subgroup was small, the observation
period short and thus do not permit a con-
clusive statement. Similarly, localization of
primary melanoma showed only some ten-
dency of discrimination for relapse. How-
ever, age and number of SLN, were far from
showing any tendency as predictive factors
for recurrence.
Our statistical analysis has shown the
very similar contribution of SLN positivity
and a high Breslow index for defining pa-
tients with high risk of early relapse. This
observation prompted the evaluation of dif-
ferent combination of these two parameters.
Patients presenting simultaneously the two
Fig. 1 e) histology and Breslow index: relapse probability (3 years): 3, 16, and 41% for subgroups with HE/IHC and
Breslow index ≤1.50, HE/IHC negative and Breslow index 1.51–3.50 and HE/IHC negative and Breslow index >3.50 or
HE/IHC positive, respectively.
e)
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